Should I buy Protagonist Therapeutics, Inc. (PTGX) stock or is it too late?

Protagonist Therapeutics, Inc. · Health Care · price $138

See the full Protagonist Therapeutics, Inc. (PTGX) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: HC Wainwright & Co. — 60% of its targets hit on this sector (329 calls tested). It aims for $170 (+23 %), call made on September 1, 2026, maturing on September 1, 2027 (43 d ago).

The 2 reliable analysts $177+28 %

The 7 other firms $180+30 %

How to read it: the 2 reliable firms are not filtered by optimism — 2 aim above the price, 0 below, hence their $177 median. “The 7 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Protagonist Therapeutics, Inc.

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
JP Morgan	86 %	+69.0 %	7	$106 -23%
HC Wainwright & Co.	88 %	+67.8 %	33	$170 +23%
JMP Securities	71 %	+40.9 %	14	$69 -50%
BMO Capital	62 %	+14.5 %	8	$190 +37%
SVB Leerink	33 %	+13.3 %	6	—

In short — Should you invest in Protagonist Therapeutics, Inc.? Is it too late, still worth it? Analysts are overwhelmingly positive (100% buy, median target $180, i.e. +30%), and the most reliable on PTGX targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

100% of analysts rate it a buy (Buy consensus, 9 ratings) — a sign of market conviction.
Median price target $180, i.e. +30% from the current price ($138).
The most reliable firm on PTGX, Wedbush (100% hit rate, 2 scored calls), targets $173 (call made on August 10, 2026, maturing on August 10, 2027) (+25%) in its most recent call, and $86 (call made on October 28, 2025, maturing on October 28, 2026) (-38%) in the one coming due soonest.

⚠️ Reasons to hesitate

A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.
A near-unanimous consensus leaves little room for positive surprise — a lot of optimism is already baked in.

The analyst consensus on PTGX

Median target $180 (+30%) · 9 ratings · Buy consensus

Strong Buy00%

Buy9100%

Hold00%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Protagonist Therapeutics, Inc. now?

We won't decide for you. The facts: 100% of analysts rate it a buy, median target $180 (+30%), and Wedbush (most reliable on PTGX, 100%) targets $173. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Protagonist Therapeutics, Inc.?

Not according to analysts: the median target ($180) is still +30% above the current price ($138) (most reliable on PTGX: Wedbush, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Protagonist Therapeutics, Inc. still worth investing in?

It depends on the gap between the price ($138) and its estimated value: analysts target $180 on median (+30%), with 100% buys (most reliable on PTGX: Wedbush, 100%). Cross-check with their real reliability on PTGX and the cautions above. Information, not advice.

What's the main risk in buying PTGX?

A 12-month target is not a guaranteed path: the price can fall in the meantime.

→ Go deeper: the full Protagonist Therapeutics, Inc. profile (consensus, analyst reliability, price target, performance).